Ascentage Pharma has received clearance from the FDA and EMA to conduct a Phase III study of lisaftoclax in combination with azacitidine for higher-risk myelodysplastic syndrome (HR-MDS). The GLORA-4 trial is enrolling patients globally, aiming to address the unmet need for targeted therapies in HR-MDS. This study could revolutionize treatment for this condition. Lisaftoclax is a promising Bcl-2 inhibitor with potential global approval, reshaping the treatment landscape for higher-risk MDS patients. The trial is led by global co-investigators and aims to provide new insights for managing higher-risk MDS.

Lisaftoclax is a novel Bcl-2 inhibitor that has shown promising clinical benefits and tolerability in earlier studies. It is currently being studied in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS). The GLORA-4 trial, a Phase III study, is enrolling patients globally and could potentially provide a new treatment option for patients with HR-MDS. The study is being conducted by leading investigators in the field and aims to address the urgent unmet medical need for innovative therapies in MDS. Lisaftoclax has the potential to change the treatment paradigm for higher-risk MDS patients globally.

Read more at GlobeNewswire: Ascentage Pharma Announces Global Registrational Phase III